The launch of BrightMeds GLP-1 represents a crucial shift in how physicians handle type 2 diabetes . This new medication class provides a distinctive way of working that not only decreases glucose but can facilitate weight loss and enhance cardiovascular outcomes. Early data suggest this therapy